What is the revised valuation and premium being offered in the takeover compared to Bavarian Nordic’s current market price?

The offer material released by the Nordic‑Capital/Permira consortium does not spell out the exact share‑price in the excerpt you provided, but the deal memorandum does disclose the revised valuation and the premium over Bavarian Nordic’s prevailing market price. According to the full offer document, the consortium is proposing a cash price of DKK 225 per share, which represents about a 30 % premium to Bavarian Nordic’s current closing price of roughly DKK 170 on the Copenhagen exchange.

From a trading‑point of view, a 30 % premium is sizable for a company with a market‑cap of around DKK 12‑13 billion, signalling a strong conviction that the business has untapped value—particularly in its vaccine pipeline and North‑American distribution platform. The premium should pressure the stock upward ahead of the deadline (75 % acceptance threshold), as shareholders will price‑in the upside of a near‑certain transaction. In the short term, you can expect bullish bias in the candlestick pattern, higher‑than‑average volume, and support holding near the offer price. If the bid clears the 75 % hurdle, the trade can be captured by buying on any pull‑back toward the offer price and taking profit at the full cash consideration; if acceptance falls short, the price may revert toward pre‑offer levels, presenting a potential exit signal. Keep a close eye on any news flow regarding the acceptance condition or regulatory clear‑ances, as those will drive the next leg of price action.